An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis. An Update of the 2011 Clinical Practice Guideline
- PMID: 26177183
- DOI: 10.1164/rccm.201506-1063ST
An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis. An Update of the 2011 Clinical Practice Guideline
Erratum in
-
Erratum: An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis. An Update of the 2011 Clinical Practice Guideline.Am J Respir Crit Care Med. 2015 Sep 1;192(5):644. doi: 10.1164/rccm.1925erratum. Am J Respir Crit Care Med. 2015. PMID: 26325160 No abstract available.
Abstract
Background: This document updates the American Thoracic Society/European Respiratory Society/Japanese Respiratory Society/Latin American Thoracic Association guideline on idiopathic pulmonary fibrosis treatment.
Methods: Systematic reviews and, when appropriate, meta-analyses were performed to summarize all available evidence pertinent to our questions. The evidence was assessed using the GRADE (Grading of Recommendations, Assessment, Development and Evaluation) approach and then discussed by a multidisciplinary panel. Predetermined conflict-of-interest management strategies were applied, and recommendations were formulated, written, and graded exclusively by the nonconflicted panelists.
Results: After considering the confidence in effect estimates, the importance of outcomes studied, desirable and undesirable consequences of treatment, cost, feasibility, acceptability of the intervention, and implications to health equity, recommendations were made for or against specific treatment interventions.
Conclusions: The panel formulated and provided the rationale for recommendations in favor of or against treatment interventions for idiopathic pulmonary fibrosis.
Comment in
-
An Important Step Forward, but Still a Way to Go.Am J Respir Crit Care Med. 2016 Feb 1;193(3):340-1. doi: 10.1164/rccm.201509-1763LE. Am J Respir Crit Care Med. 2016. PMID: 26829426 No abstract available.
-
Idiopathic Pulmonary Fibrosis and Prothrombotic State.Am J Respir Crit Care Med. 2016 Feb 1;193(3):341-2. doi: 10.1164/rccm.201509-1835LE. Am J Respir Crit Care Med. 2016. PMID: 26829427 No abstract available.
-
Reply to "An Important Step Forward, but Still a Way to Go".Am J Respir Crit Care Med. 2016 Feb 1;193(3):342. doi: 10.1164/rccm.201510-2010LE. Am J Respir Crit Care Med. 2016. PMID: 26829428 No abstract available.
-
Reply to "An Important Step Forward, but Still a Way to Go" and "Idiopathic Pulmonary Fibrosis and Prothrombotic State".Am J Respir Crit Care Med. 2016 Feb 1;193(3):343. doi: 10.1164/rccm.201510-2049LE. Am J Respir Crit Care Med. 2016. PMID: 26829429 No abstract available.
-
Can Warfarin Be Used in the Treatment of Pulmonary Embolism in Idiopathic Pulmonary Fibrosis?Am J Respir Crit Care Med. 2016 Apr 1;193(7):810-1. doi: 10.1164/rccm.201511-2267LE. Am J Respir Crit Care Med. 2016. PMID: 27035785 No abstract available.
-
Reply: Can Warfarin Be Used in the Treatment of Pulmonary Embolism in Idiopathic Pulmonary Fibrosis?Am J Respir Crit Care Med. 2016 Apr 1;193(7):811. doi: 10.1164/rccm.201601-0078LE. Am J Respir Crit Care Med. 2016. PMID: 27035786 No abstract available.
-
Can Bisphosphonates Prevent Vitamin K Antagonist Toxicity in Patients with Idiopathic Pulmonary Fibrosis?Am J Respir Crit Care Med. 2017 Jan 15;195(2):269-270. doi: 10.1164/rccm.201605-1074LE. Am J Respir Crit Care Med. 2017. PMID: 28084819 No abstract available.
-
Reply: Can Bisphosphonates Prevent Vitamin K Antagonist Toxicity in Patients with Idiopathic Pulmonary Fibrosis?Am J Respir Crit Care Med. 2017 Jan 15;195(2):271. doi: 10.1164/rccm.201608-1610LE. Am J Respir Crit Care Med. 2017. PMID: 28084827 No abstract available.
Similar articles
-
Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline.Am J Respir Crit Care Med. 2018 Sep 1;198(5):e44-e68. doi: 10.1164/rccm.201807-1255ST. Am J Respir Crit Care Med. 2018. PMID: 30168753
-
Diagnosis of Primary Ciliary Dyskinesia. An Official American Thoracic Society Clinical Practice Guideline.Am J Respir Crit Care Med. 2018 Jun 15;197(12):e24-e39. doi: 10.1164/rccm.201805-0819ST. Am J Respir Crit Care Med. 2018. PMID: 29905515 Free PMC article.
-
Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline.Am J Respir Crit Care Med. 2022 May 1;205(9):e18-e47. doi: 10.1164/rccm.202202-0399ST. Am J Respir Crit Care Med. 2022. PMID: 35486072 Free PMC article.
-
Consensus document for the diagnosis and treatment of idiopathic pulmonary fibrosis: Joint Consensus of Sociedade Portuguesa de Pneumologia, Sociedade Portuguesa de Radiologia e Medicina Nuclear e Sociedade Portuguesa de Anatomia Patológica.Rev Port Pneumol (2006). 2016 Mar-Apr;22(2):112-22. doi: 10.1016/j.rppnen.2016.01.003. Epub 2016 Feb 20. Rev Port Pneumol (2006). 2016. PMID: 26906287
-
Review of IPF diagnosis and management recommendations in Europe.Sarcoidosis Vasc Diffuse Lung Dis. 2013 Dec 17;30(4):249-61. Sarcoidosis Vasc Diffuse Lung Dis. 2013. PMID: 24351616 Review.
Cited by
-
A semi-automatic pipeline integrating histological and µCT data in a mouse model of lung fibrosis.J Transl Med. 2024 Nov 18;22(1):1040. doi: 10.1186/s12967-024-05819-y. J Transl Med. 2024. PMID: 39558387 Free PMC article.
-
Phytochemical Compounds as Promising Therapeutics for Intestinal Fibrosis in Inflammatory Bowel Disease: A Critical Review.Nutrients. 2024 Oct 25;16(21):3633. doi: 10.3390/nu16213633. Nutrients. 2024. PMID: 39519465 Free PMC article. Review.
-
Molecular imaging in experimental pulmonary fibrosis reveals that nintedanib unexpectedly modulates CCR2 immune cell infiltration.EBioMedicine. 2024 Nov 7;110:105431. doi: 10.1016/j.ebiom.2024.105431. Online ahead of print. EBioMedicine. 2024. PMID: 39515027 Free PMC article.
-
Plasma genome-wide mendelian randomization identifies potentially causal genes in idiopathic pulmonary fibrosis.Respir Res. 2024 Oct 18;25(1):379. doi: 10.1186/s12931-024-03008-5. Respir Res. 2024. PMID: 39425105 Free PMC article.
-
The providing multidisciplinary ILD diagnoses (PROMISE) study - study design of the national registry of Japan facilitating interactive online multidisciplinary discussion diagnosis.BMC Pulm Med. 2024 Oct 14;24(1):511. doi: 10.1186/s12890-024-03232-1. BMC Pulm Med. 2024. PMID: 39396941 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
